Does Rallies show Form 4 insider transactions for IDXX?

Yes. Rallies tracks IDXX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is IDXX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IDXX. It does not provide personalized investment advice.

IDXX (IDEXX Laboratories) Stock Analysis - Insider Trades

IDEXX Laboratories (IDXX) is a publicly traded Healthcare sector company. As of May 20, 2026, IDXX trades at $551.48 with a market cap of $43.05B and a P/E ratio of 40.37. IDXX moved +1.27% today. Year to date, IDXX is -18.86%; over the trailing twelve months it is +7.04%. Its 52-week range spans $356.14 to $769.98. Analyst consensus is buy with an average price target of $693.17. Rallies surfaces IDXX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading IDXX stock inside the company?

Recent IDXX insider activity includes Hunt Nimrata sold 1.76K, MAZELSKY JONATHAN JAY sold 1.28K, MAZELSKY JONATHAN JAY sold 1.09K, MAZELSKY JONATHAN JAY sold 1.67K, and MAZELSKY JONATHAN JAY sold 1.17K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

IDXX Key Metrics

Key financial metrics for IDXX
Metric	Value
Price	$551.48
Market Cap	$43.05B
P/E Ratio	40.37
EPS	$13.69
Dividend Yield	0.00%
52-Week High	$769.98
52-Week Low	$356.14
Volume	435.42K
Avg Volume	0
Revenue (TTM)	$4.45B
Net Income	$1.10B
Gross Margin	62.05%

Recent IDXX Insider Trades

Hunt Nimrata sold 1.76K (~$1.12M) on Mar 3, 2026.
MAZELSKY JONATHAN JAY sold 1.28K (~$833.51K) on Feb 26, 2026.
MAZELSKY JONATHAN JAY sold 1.09K (~$713.38K) on Feb 26, 2026.
MAZELSKY JONATHAN JAY sold 1.67K (~$1.09M) on Feb 26, 2026.
MAZELSKY JONATHAN JAY sold 1.17K (~$765.45K) on Feb 26, 2026.

Latest IDXX News

IDEXX jumps after Q1 beat and higher 2026 EPS outlook to $14.45–$14.90 — May 6, 2026
IDEXX Laboratories Beats Quarterly EPS and Revenue Estimates with 15% Pet Segment Growth — May 5, 2026
IDEXX jumps after Q1 beat and raised 2026 revenue, EPS outlook — May 5, 2026
Idexx Laboratories Posts $278.4M Q1 Profit, Boosts Annual Revenue Outlook to $4.68B–$4.76B — May 5, 2026
IDEXX slides 3.5% as traders de-risk ahead of May 5 earnings — Apr 29, 2026

IDXX Analyst Consensus

7 analysts cover IDXX: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $693.17.

Common questions about IDXX

Who is trading IDXX stock inside the company?: Recent IDXX insider activity includes Hunt Nimrata sold 1.76K, MAZELSKY JONATHAN JAY sold 1.28K, MAZELSKY JONATHAN JAY sold 1.09K, MAZELSKY JONATHAN JAY sold 1.67K, and MAZELSKY JONATHAN JAY sold 1.17K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for IDXX?: Yes. Rallies tracks IDXX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is IDXX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IDXX. It does not provide personalized investment advice.